Several anti-angiogenic drugs have been approved for use in NSCLC, such as monoclonal antibodies directed against VEGF-A/VEGFRs and small molecule tyrosine kinase inhibitors (TKIs). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.